{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 20,
  "pageCount": 58,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "industry_trends",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a stacked bar chart to show survey responses and a callout box for qualitative expert feedback.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "quote_block",
    "footnote",
    "photo"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/20",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-20",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "In order to survive, they must find a differentiated path; for instance, smartly leverage its own capability or be a pilot in a niche TA.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-60cae631d769",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.04,
        "y": 0.21
      },
      "kind": "chart",
      "text": "Perspectives on the future trend of homogeneous competition in China* (N=101)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9d8e0c1-b85e-4e41-b752-d74a95ad7f79",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.92,
        "x": 0.04,
        "y": 0.85
      },
      "kind": "disclaimer",
      "text": "Note: *Survey questions: China in-trial products are more and more homogeneous as many in-trial / in-market products are of same target and mechanism (e.g., PD-1), which brings significant challenges to future commercialization.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "26ca5db1-6d57-450b-96bc-25be1c473e93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Percent of respondents: 70%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-68cff110ce9a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.44,
        "x": 0.52,
        "y": 0.21
      },
      "kind": "quote",
      "text": "Market feedback",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84dd8775-3702-4737-b307-393326f42622",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "In capital market, investors are beginning to realize that companies are mostly playing with repetitive technologies and lack of true innovation. In the future, investors tend not to invest in me-copy drugs, further cutting down the number of homogeneous trials. - CEO, a Chinese biopharma, Sept. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbd-66d4f7d8ee22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5af0e4cc-3406-48ff-a2cf-45fe8ea13084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.04,
        "y": 0.03
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5069f6d8-4f89-4539-a173-f7b6cbb090a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Percent of respondents",
      "numberRaw": "70%",
      "numberKind": "percent",
      "actionTitle": "~70% of respondents also believe that homogeneous competition will relieve in next 5 years with company focus shifting to innovative, differentiated and China-specific drugs",
      "calloutText": "In order to survive, they must find a differentiated path; for instance, smartly leverage its own capability or be a pilot in a niche TA.",
      "numberScale": null,
      "numberValue": 70,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}